FR-167653, a selective p38 MAPK inhibitor, exerts salutary effect on liver cirrhosis through downregulation of Runx2
- 1 June 2007
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 87 (6) , 591-601
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in miceCytokine, 2005
- Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in ratsHepatology, 2004
- Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined dietBiochemical and Biophysical Research Communications, 2004
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- p38 Mitogen-activated Protein Kinase Stabilizes mRNAs That Contain Cyclooxygenase-2 and Tumor Necrosis Factor AU-rich Elements by Inhibiting DeadenylationJournal of Biological Chemistry, 2003
- Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-β and bone morphogenetic proteinOncogene, 2002
- p38 MAPK mediates the regulation of α1(I) procollagen mRNA levels by TNF‐α and TGF‐β in a cell line of rat hepatic stellate cells1FEBS Letters, 2002
- TAK1/JNK and p38 have opposite effects on rat hepatic stellate cellsHepatology, 2001
- Involvement of the p38 Mitogen-activated Protein Kinase Pathway in Transforming Growth Factor-β-induced Gene ExpressionJournal of Biological Chemistry, 1999
- Identification of High– and Low–Risk Patients Before Liver Transplantation: A Prospective Cohort Study of Nutritional and Metabolic Parameters in 150 PatientsHepatology, 1997